Addex Therapeutics Publishes Annual Report 2013

Addex Therapeutics Reports 2013 Financial Results

Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms

Addex and NIDA enter collaboration to advance ADX71441 & ADX88178 in drug abuse and addiction

Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression

Addex ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease

Addex Therapeutics First Half 2013 Financial Results

Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1

Addex Therapeutics raises CHF3.2 million in a Private Placement to International Institutional Investors

Addex Completes Restructuring to Focus on Capturing Potential Upside from its Partnered Asset and CEO Steps Down